Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis

Fig 5

Scatter plot of incremental cost against QALY gained EGFR mutation-guided afatinib versus EGFR mutation-guided erlotinib.

QALY: quality-adjusted life-year; WTP: willingness-to-pay.

Fig 5

doi: https://doi.org/10.1371/journal.pone.0247860.g005